HIV i-Base

HIV i-Base i-Base improve's the quality of care for HIV positive people. We are an independent treatment information and activist project. Access to information is a right.

HIV i-Base is a treatment advocacy group, HIV positive-led and committed to providing timely HIV treatment information to HIV positive people and healthcare professionals. We publish information for HIV positive people and for health workers and all our publications are available free in print and online. We are also involved in scientific and policy meetings, presentations, training and workshops. We are also connected with many other activist groups in the UK and internationally. The information service (by phone, email, and online) provides individualised information to HIV positive people and their families, friends and advocates. i-Base produce resources based on latest research. For information to be useful and effective it needs to be accurate, up-to-date and in appropriate language. For most people this needs to use everyday language. For medical professionals this needs to be more technical. We follow the latest research, review and advise on treatment guidelines, alert to updated information, and work with other people living with HIV to adapt and use new information. All i-Base materials are copyright-free for non-for-profit use. They are written to be clear, easy to understand, evidenced-based and impartial. They are distributed free at point of access and accessible to all those in need. The website now includes translations into over 35 languages produced by partner organisations globally. All our advisory boards include HIV positive people and healthcare professionals. As a peer-led project most of people working at i-Base all also HIV positive. The i-Base website is designed to be fast and easy to access., with quick and stable downloads to people using dial-up connections or low speed connections in the UK or internationally. The i-Base Q&A information service is well established with over 3000 questions online. Activists at i-Base are connected to other community and research networks and collaborate on national and international research and policy programmes. Who participates in i-Base? i-Base is part of a broad network that includes:

• HIV-positive people
• community educators and activists
• healthcare professionals
• researchers and scientists
• commissioners and purchasers; and
• policy-makers. i-Base works with activists in other countries to help develop treatment education programmes. All i-Base material is provided free and has a copyright waiver for non-for-profit use. Therefore, in addition to the approximately 40,000 patient guides printed and distributed in the UK each year, i-Base also collaborates with many international groups to produce translations and adaptations of all materials. These resources, based on i-Base publications, have now been translated into more than 30 languages, and adapted for and distributed in many different settings. These translations are very often the first publications on HIV treatment and care in a country’s national or regional language produced by an HIV positive community organisation. Background

Currently in the UK, more than 100,000 people are living with HIV, one-third of who are not yet diagnosed. Around 7,000 people are diagnosed each year. Although HIV treatment and care in the UK are high quality and accessible particularly when compared to the rest of the world, too many people start treatment later than recommended to get the optimum response. About 30% of people are diagnosed late with a CD4 count of less than 350. Treatment is safe and effective, but 500 people in the UK each year still die from HIV-related causes. Half of these are due to late diagnosis. What is treatment literacy? Treatment literacy is essential to anyone challenged with the management of a chronic health problem, whether it is HIV infection, cancer, diabetes, hepatitis, or hypertension. Good treatment information helps people to make informed decisions about when to begin treatment and what treatment to choose, to understand how medicines work, and thus to understand the critical issues of adherence, possible medication interactions, and effective management of side effects if and when they occur. During the past decade, health researchers have defined concepts such as “functional health literacy”, and have documented the link between health literacy, health empowerment, and social capital to health outcomes. For example, a study published in 2000 showed that people living with HIV who had less ability to understand medical information and instructions were less likely to be taking antiretrovirals, less likely to have undetectable viral load even with treatment, and reported lower CD4 cell counts, poorer overall health outcomes, and greater incidence of hospitalisation (Kalichman, JAIDS 2000). Even after making allowance for years of education, lower health literacy was associated with poorer knowledge of HIV-related health status, poorer AIDS-related treatment knowledge, and more negative health care perceptions, misconceptions and experiences. Literacy and empowerment about HIV treatment decisions are especially needed by people who have limited access to health care, limited economic and social power to express their needs, and limited information or networks to support knowledge about options for health. The good news is that, for most people, current treatment can lead to a normal or near-normal life expectancy, and current research is investing in better, more effective and more tolerable treatments. HIV treatment requires much more care than nearly every other type of medicine. Missing HIV doses can lead to resistance making those treatments much less effective. Resistance to one drug often generates resistance to similar drugs in that class. So, although over 25 drugs have been approved to treat HIV, they only combine to offer a few successive combinations. This shows the importance of support and information to ensure that as HIV-positive people, we are actively involved in our own healthcare, including choice of treatment. The goal of treatment is not just reducing viral load and improving CD4 counts, reducing illness and extending our life expectancy – it is for this to improve our quality of life. HIV treatment and care can be complex. But if treatment is used carefully, then any combination has the potential to be lifelong. Many healthcare systems responsible for delivering care have limitations of time, communication or trust. Quality of healthcare provision can also be an issue in any clinic. One way to tackle these challenges is to ensure that people living with HIV have a high degree of health literacy and empowerment in their interactions with the health care system, and in their decision-making related to health and HIV treatment. Globally, particularly in countries with large-scale epidemics and fragile healthcare systems, there is a far more urgent need to develop HIV treatment literacy and empowerment. This has lead to many thousands of community-based organisations, many led by people living with HIV, being engaged in producing and distributing HIV treatment information. The past decade has provided a valuable lesson: that proper access and use of combination antiretroviral therapy requires the involvement and leadership by people living with HIV. Advances in global access to treatment has been driven as much by the treatment literacy and advocacy of people living with HIV as much as it has by the good will of governments, multinational organisations, pharmaceutical companies, global philanthropy, and health workers. i-Base is a partner in these global efforts, and is proud to contribute to these on-going struggles and successes.

i-base.info/htb/54541 – PrEP efficacy depends on adherence not biology, PrEP access depends on politicsAIDS 2026 was an ...
11/10/2026

i-base.info/htb/54541 – PrEP efficacy depends on adherence not biology, PrEP access depends on politics

AIDS 2026 was an opportunity to catch up on the latest research on PrEP, thanks to a great talk by Raphael Landovitz from David Geffen School of Medicine at UCLA. An important focus was the science behind the recent change in dosing advice for women and some transgender people. These groups have had different and more difficult prescribing guidance for many years, but Landowitz challenged the research behind this, describing it as “the story we told badly the first time”. Researchers previously believed that PrEP was less effective in cis women due to biological differences to do with low drug levels in vaginal tissue. But more recent research shows PrEP is effective in everyone regardless of s*x or gender, as long as you have good adherence. Over 90% efficacy was reported in both men and women when adherence involved 4 or more pills a week.

New analyses led to both the 2025 UK and EACS guidelines recommending that 2:7 event-based dosing can be used for receptive vaginal s*x. They also recognised that fewer doses than 7 per week might be just as effective. Landovitz went further, saying, “We may soon be seeing recommendations to harmonise 2:1:1 dosing across populations.”

A review of the PrEP pipeline included once-monthly oral alimatravir, once-yearly lenacapavir and 4-monthly cabotegravir injections, and weekly oral lenacapavir, which has already been submitted to the FDA. Results on a re**al tenofovir do**he are expected within 6 months and there are early study results on TAF/elvitegravir inserts (suppositories) with and without doxycycline.

Landovitz also talked about the political blocks to access following cuts to global funding from the US. Both new PrEP initiations and the numbers of people retained on PrEP have fallen by 40% compared to 2024 – in many of the countries with the highest rates of new HIV infections. The session concluded by emphasising that the most important aspect of PrEP today is widespread global access and the political fight needed to achieve this.

You can read about the research from this talk in more detail at the link above.

i-base.info/htb/54769 – New US HIV research plan: priority shifts to MAGA-aligned implementation studiesThe US NIH Offic...
08/10/2026

i-base.info/htb/54769 – New US HIV research plan: priority shifts to MAGA-aligned implementation studies

The US NIH Office of AIDS Research has set out its plans for HIV research until 2030 in a new report. The preface by Jay Bhattacharya says that research will now follow MAGA ideology. NIH will also now focus on implementation science, rather than basic and clinical science. This could signal less research into HIV medicines and vaccines. Implementation science involves using the scientific knowledge we already have and incorporating it into care and services, but MAGA goals risk missing key populations. This change in priority casts uncertainty over whether any research into new compounds, vaccines or trials will be funded.

The report’s own infographic shows how behind the US is in their HIV response. Though it doesn’t mention the UNAIDS 95:95:95 targets, the data shows that in 2022 (the latest data available), the US had only reached 87:75:76. This is lower than many African countries who have much larger HIV epidemics.

HTB homepage • Conference reports • Articles by subject • Subscribe New US HIV research plan: priority shifts to MAGA-aligned implementation studies 5 October 2026. Related: Early access, Treatment strategies, Guidelines, Activism & advocacy. Simon Collins, HIV i-Base On 2 October 2026, the US...

i-base.info/htb/54709 – Stopping ART as part of HIV cure-related research: experiences from the RIO studyThe research te...
06/10/2026

i-base.info/htb/54709 – Stopping ART as part of HIV cure-related research: experiences from the RIO study

The research team from the RIO study has published a report on how it has affected participants’ quality of life. Participants must stop their usual HIV treatment (ART) to test if a new treatment, in this case using bNAbs, continues to suppress their viral load. This is called an analytic treatment interruption (ATI). This can be a difficult mental and lifestyle change for people who have been taking the same ART every day for many years. It also involves not knowing when their viral load might become detectable. There has not been much research on the psychological impact of this.

Although ATIs usually last only a few weeks or months, some participants in the RIO study have been able to safely remain off ART for several years. This has raised issues that weren’t thought of when the study was designed, including the difficulties of close monitoring and living with uncertainty over a really long time. Also, after being off ART for so long, it can be a challenge to return to the habit of good adherence.

A better understanding of these experiences can hopefully help when planning future research. Read the full article at the link above.

HTB homepage • Conference reports • Articles by subject • Subscribe Stopping ART as part of HIV cure-related research: experiences from the RIO study 4 October 2026. Related: Journal scan, Treatment strategies, Cure-related research. Simon Collins, HIV i-Base A paper by Jesal Gohil and colleag...

i-base.info/htb/54678 – US to end HIV support to Zimbabwe today: “This is not a future risk – it is a present crisis”The...
30/09/2026

i-base.info/htb/54678 – US to end HIV support to Zimbabwe today: “This is not a future risk – it is a present crisis”

The impact of this decision by the US was discussed in a CHANGE community webinar last week. It presents an impending crisis to HIV care and the wider health system in Zimbabwe.

The US withdrew from further discussions after the Zimbabwean government refused to accept the terms of the Trump administration’s new HIV funding agreement. The proposed deal would have granted the US access to Zimbabwe’s commercial assets, such as sensitive health data, important minerals and biological samples, with no guarantee that research from the latter will be used to benefit Zimbabwe itself. Though many countries have signed the new deal, Ghana, Zambia and Namibia have not.

90% of Zimbabwe’s HIV treatment and PrEP coverage has been directly supported by US PEPFAR funding. Without this, the country will be short of roughly US$80-100 million per year. Over five years this could mean more than 100,000 preventable deaths and 50,000 new HIV infections.

The meeting noted that the US is responsible for this diplomatic failure and the resulting catastrophic situation for Zimbabwe. Although the US Congress is aware of the problem, it appears to be doing nothing about it.

HTB homepage • Conference reports • Articles by subject • Subscribe US to end HIV support to Zimbabwe this week: “This is not a future risk – it is a present crisis” 25 September 2026. Related: Treatment access, Activism & advocacy. Paul Clift, EATG and Simon Collins, HIV i-Base On 24 Se...

27/07/2026

: i-base.info/htb/54322 – Activists challenge US government over “shameful” PEPFAR cuts

The protest took place during a session organised by the US government, whose presence at the conference had already been criticised in an open letter. Activists took to the stage with signs and chants, interrupting the speaker, Jeff Graham. Graham is the acting US Global AIDS Coordinator responsible for PEPFAR and the head of the US delegation to the conference.

Asia Russell, executive director and founder of Health Gap, addressed Graham and other speakers: “We will not be erased. PEPFAR’s own programme data show the deadly harms of this approach. Your own data show it – although you have repressed it.”

As well as activists from Health GAP, the protest was led by Treatment Action Campaign and Housing Works Inc. – including by people from the countries directly affected by global aid cuts. Signs read, ‘Trump’s cuts kill people with AIDS, restore PEPFAR now,’ and ‘End Trump’s attacks on key populations, we will not be erased.’

It’s unlikely that attempts after the protest to justify the ‘America First Global Health Strategy’ as progressive or supportive to the HIV response were convincing. And the evidence speaks for itself. Studies presented at the conference detail exactly how US funding cuts have withdrawn vital HIV care and prevention from some of the most at-risk people. Full report with photos at the link above.

 : i-base.info/htb/54286 – High efficacy continues in open-label extensions to lenacapavir phase 3 PrEP studiesEarly hea...
27/07/2026

: i-base.info/htb/54286 – High efficacy continues in open-label extensions to lenacapavir phase 3 PrEP studies

Early headlines from the conference include the latest from the PURPOSE 1 and 2 studies, which tested 6-monthly injectable lenacapavir for HIV prevention. These updates are from the phase during which all participants were able to choose to take lenacapavir, after the blind randomised phase ended.

95% of people eligible for lenacapavir across both studies chose to have it and no new safety concerns were reported. In PURPOSE 1, no new infections were reported. This study’s participants were women in Uganda and South Africa. Their adherence to injections was high at 96%.

PURPOSE 2 studied the drug in cis men and trans and non-binary people who have s*x with men, in six countries across North and South America and South Africa. There was one new HIV transmission in this phase, however details on this case are currently limited. We know that injections were on time but the drug levels are not yet available. Adherence to injections at week 52 was 92%.

This is good news as the data continues to show that lenacapavir is highly effective. It has a significantly lower HIV transmission rate compared to oral PrEP. Full details will be available at the conference after 30th July. Read more at the link above.

HTB homepage • Conference reports • Articles by subject • Subscribe AIDS 2026: High efficacy continues in open label extensions to lenacapavir phase 3 PrEP studies 21 July 2026. Related: Conference reports, HIV prevention and transmission, Intl AIDS 26th Rio 2026. Simon Collins, HIV i-Base On ...

i-base.info/aids-2026-programme-highlights-to-look-out-for –   at  : Our highlights of an exciting programmeThe Internat...
21/07/2026

i-base.info/aids-2026-programme-highlights-to-look-out-for – at : Our highlights of an exciting programme

The International AIDS Conference from 26-30 July 2026 is in Rio de Janeiro this year, with an official theme of ‘Rethink. Rebuild. Rise.’ As well as clinical science, there will be a strong focus on the social side. This includes how global systems and policy affect key populations and treatment access. And the Global Village, a space where activists come together with scientists, will showcase diverse community responses to HIV via over 200 events and exhibitions.

We are looking forward to reporting this year’s programme of more than 150 sessions and over 2400 posters. Our highlights include new HIV drugs, such as once-weekly oral islatravir/lenacapavir, 6-monthly injectable lenacapavir + bNAbs, and daily oral bictegravir/lenacapavir which will simplify ART. Cure research, including two new cures cases from stem-cell transplant and more updates from the RIO study. And other studies on HIV drugs that are already approved, which will present data in specific populations.

The latest PrEP research will include follow-up from studies using injectable lenacapavir, including data on how it’s being accessed in the real world. Also, injectable cabotegravir, a new once-monthly pill called alimatravir, and early results from a trial using bNAbs for PrEP in women in South Africa.

Since this year’s theme is heavily influenced by the global funding crisis, it’s no surprise that several sessions will cover responses to it. Talks will detail the real-world impact of aid cuts, for example, the effect on HIV treatment for children across Africa. Our reports will also include some of the impressive number of transgender health studies and studies on chems*x and harm reduction. To read about our programme highlights in more detail, please click the link above.

*x

AIDS 2026: Programme highlights to look out for 20 July 2026. Related: News. Simon Collins, HIV i-Base The AIDS 2026 conference is being held from 26-30 July 2026 in Rio de Janeiro with an exciting programme that is already posted online. [1] Introduction Held every two years, the International AIDS...

CROI 2026: i-base.info/htb/53923 – Low levels of bNAbs detected in re**al tissue up to 46 weeks post infusionThese level...
16/07/2026

CROI 2026: i-base.info/htb/53923 – Low levels of bNAbs detected in re**al tissue up to 46 weeks post infusion

These levels were discovered in six people taking part in a cure-related HIV study. bNAbs (broadly neutralizing antibodies) are proteins made by the immune system and are used in HIV cure research to block the virus.

Although the levels were likely too low to affect HIV, it shows the importance of checking bNAb levels in tissue samples. Perhaps bNAb levels could last even longer in other parts of the body?

HTB homepage • Conference reports • Articles by subject • Subscribe CROI 2026: Low levels of bNAbs detected in re**al tissue up to 46 weeks post infusion 1 May 2026. Related: Conference reports, Cure-related research, CROI 33 (Retrovirus) 2026. Simon Collins, HIV i-Base Low levels of the long-...

i-base.info/htb/54062 – New guidelines on persistent low-level viral load in people living with HIV (2026)Published in L...
14/07/2026

i-base.info/htb/54062 – New guidelines on persistent low-level viral load in people living with HIV (2026)

Published in Lancet HIV, the guidelines have been developed by an international panel of more than 100 experts. They aim to agree a definition of persistent low-level viraemia (LLV) and provide practical guidance to manage it. LLV is broadly defined as persistent viral load between 200 and 1000 copies/mL.

Some of the new ongoing risk and management options include: further viral load and/or resistance testing, deciding if the cause is due to viral production (non-suppressible) vs ongoing replication (suppressible), and adherence support. The latter needs to be provided in a non-confrontational way that maintains the trust between a health provider and the person living with HIV.

These guidelines are welcomed as LLV is one of the most difficult clinical challenges in people on HIV treatment. The document also discusses some of the current gaps in knowledge of LLV.

HTB homepage • Conference reports • Articles by subject • Subscribe New guidelines on persistent low-level viral load in people living with HIV (2026) 12 June 2026. Related: Treatment strategies, Guidelines, Drug resistance. Simon Collins, HIV i-Base New consensus guidelines on the definition ...

14/07/2026

Address

PO Box 81147
London
E1W9XD

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+448088006013

Alerts

Be the first to know and let us send you an email when HIV i-Base posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organisation

Send a message to HIV i-Base:

Shortcuts

Share